Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Rubin

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
The New England Journal of Medicine|March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K Chan, Mark F Brady, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2017
CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG StudyChaan S Ng, Zheng Zhang, Susanna I Lee, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
The New England Journal of Medicine|March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K Chan, Mark F Brady, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2017
CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG StudyChaan S Ng, Zheng Zhang, Susanna I Lee, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Pageof 6